Immorna
Latest round
- Series A
Last raised
- Feb 2023
Total raised
- $115M
Investors
- 11
About Immorna
Based in Hangzhou, China, and established in 2019, Immorna is a biotechnology company that focuses on the development of RNA-based therapeutics and vaccines. In March 2020, it established a chemistry, manufacturing, and controls (CMC) lab in Hangzhou, and in August 2020, it established an R&D lab in Shanghai. And in December 2021, it established the good manufacturing practice (GMP)-level factory. And then, in March 2022, it received FDA investigational new drug (IND) Clearance for JCXH-211. Professor, Zihao, Wang, the company's CEO, has over 14 years of biotech R&D and leadership experience and developed self-replicating mRNA CMC platform. Immorna engages in the R&D of RNA-based therapeutics and vaccines. It developed CMC platform for RNA synthesis, purification, and analytical testing that is suited for clinical and commercial development. And, it has developed RNA delivery vehicles, including polymers and lipid nanoparticles featuring multiple proprietary ionizable cationic lipids suitable for intramuscular, intravenous and tissue-targeting delivery. Those RNA drugs are treated for cancer immunotherapy, infectious diseases, rare genetic diseases, and medical cosmetology. Moreover, it provides contract development manufacturing (CDMO ) services, based on its own RNA and LNP platform, and services including sequence design, customized analytical assay development, DNA template manufacturing, mRNA/ LNP production and purification.
Who invested in Immorna
11 investors across 3 rounds
See all investors in Immorna
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Immorna
Who invested in Immorna?
Immorna has 11 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Immorna raised?
Immorna has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Immorna last raise money?
Immorna's most recent round on record is a Series A, in Feb 2023.
What does Immorna do?
Based in Hangzhou, China, and established in 2019, Immorna is a biotechnology company that focuses on the development of RNA-based therapeutics and vaccines.
Where is Immorna headquartered?
Immorna is headquartered in Hangzhou, China.
Which VCs invest in companies like Immorna?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Immorna's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Immorna? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.